key: cord-0963582-u7kwsynz
authors: Zork, Noelia M.; Markan, Amrita; Sheen, Jean-Ju; Aubey, Janice; Saiman, Lisa; Goffman, Dena
title: Serial surveillance for SARS-CoV-2 in hospitalized antepartum women
date: 2021-04-24
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.04.222
sha: b4b6514741c198e7fadb0af670048d74c4c96457
doc_id: 963582
cord_uid: u7kwsynz

nan

Serial surveillance for SARS-CoV-2 in hospitalized antepartum women

During New York City's (NYC) first wave of COVID-19 in the spring of 2020, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center instituted universal SARS-CoV-2 testing for all admitted pregnant women. 1 No visitors were permitted on the antepartum unit during the peak of the pandemic. As local infection rates decreased, 1 support person was allowed for each patient. During NYC's second COVID-19 wave, which began in October 2020, the 1-support-person policy was maintained. Owing to concerns that hospitalized pregnant women could be within the SARS-CoV-2 14-day incubation period on admission or could become infected by asymptomatic support persons, polymerase chain reaction (PCR) testing for SARS-CoV-2 via nasopharyngeal swabs was obtained every 5 days for all women at >23 weeks' gestation who had prolonged hospitalizations for obstetrical indications. In this letter, we report the outcomes of repeat testing.

From November 23, 2020, to March 3, 2021, results of all SARS-CoV-2 PCR swabs sent from the antepartum unit were collected. Serial testing was only performed for patients whose admission test was negative and who could require urgent delivery, because an unrecognized SARS-CoV-2 infection could have considerable anesthetic and neonatal implications. Results were evaluated in the context of the local 7-day positivity rate for our hospital's ZIP code (10032). Our visitor policy is presented in the Table. RESULTS:

A total of 169 swabs were performed on 72 patients. None of these patients became SARS-CoV-2 positive during their hospitalization. Patients were retested an average of 2.34 times (range, 1e13). The 7-day positivity rate for our hospital's zip code was 5.3% on November 28, 2020 and peaked at 10.2% on January 8, 2020. These rates were higher than the overall positivity rate for Manhattan and all of NYC during the same time. 2

Despite allowing visitors to the antepartum unit during a time of high local positivity rate for SARS-CoV-2, hospitalized pregnant women did not become infected. This may reflect the effectiveness of visitor screening for COVID-19 symptoms upon presenting to the hospital, the self-monitoring of symptoms by our patients' family members, the enforcement of universal masking of patients and visitors, social distancing, and hand hygiene. This testing practice, intended to promote safety, proved to be costly in terms of testing resources and staff workload without adding clear benefit. In addition, several women refused repeat testing owing to discomfort. Similar findings were noted in a larger nonobstetrical patient population. Serial SARS-CoV-2 testing was performed every 5 days in 4580 hospitalized patients in a large tertiary care center, and 96.9% had negative results. 3 Only 1% converted from a negative to a positive test during admission. We plan to continue to test all admitted pregnant women for SARS-CoV-2 and to perform a second test on hospital day 5, in case a patient is admitted during the incubation period for SARS-CoV-2. Subsequent testing for SARS-CoV-2 will be performed for patients with signs, symptoms, or exposure or in anticipation of delivery. We hope our experience will be useful to other institutions faced with similar challenges. 

Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals

COVID-19 data

COVID-19 serial testing among hospitalized patients in a midwest tertiary medical center

All rights reserved